Galapagos NV (Euronext & LSE: GLPG), a genomics-based drug discovery company, announced today that Galapagos’ service division, BioFocus, has entered into a three-year collaboration with Roche. This new agreement builds on the successful working history between Roche and BioFocus. Under the terms of the agreement, BioFocus will supply Roche with exclusive chemical compound libraries. Financial terms were not disclosed.
